10859283

Source:http://linkedlifedata.com/resource/pubmed/id/10859283

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0008976, umls-concept:C0155626, umls-concept:C0175566, umls-concept:C0256103, umls-concept:C0288672, umls-concept:C0562508, umls-concept:C0678536, umls-concept:C0679199, umls-concept:C1257890, umls-concept:C1627358, umls-concept:C2349975
pubmed:issue	24
pubmed:dateCreated	2000-7-13
pubmed:abstractText	Low-dose alteplase with standard-dose abciximab enhances reperfusion 90 minutes after acute myocardial infarction (MI). We combined standard-dose abciximab with low-dose reteplase for acute MI in 2 phases. Two heparin doses were also explored.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0147763
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Anticoagulants, http://linkedlifedata.com/resource/pubmed/chemical/Fibrinolytic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin Fab Fragments, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Tissue Plasminogen Activator, http://linkedlifedata.com/resource/pubmed/chemical/abciximab, http://linkedlifedata.com/resource/pubmed/chemical/reteplase
pubmed:status	MEDLINE
pubmed:month	Jun
pubmed:issn	1524-4539
pubmed:issnType	Electronic
pubmed:day	20
pubmed:volume	101
pubmed:owner	NLM
pubmed:pagination	2788-94
pubmed:dateRevised	2006-11-15
pubmed:meshHeading	pubmed-meshheading:10859283-Aged, pubmed-meshheading:10859283-Antibodies, Monoclonal, pubmed-meshheading:10859283-Anticoagulants, pubmed-meshheading:10859283-Blood Transfusion, pubmed-meshheading:10859283-Coronary Angiography, pubmed-meshheading:10859283-Coronary Circulation, pubmed-meshheading:10859283-Drug Therapy, Combination, pubmed-meshheading:10859283-Female, pubmed-meshheading:10859283-Fibrinolytic Agents, pubmed-meshheading:10859283-Hemorrhage, pubmed-meshheading:10859283-Humans, pubmed-meshheading:10859283-Immunoglobulin Fab Fragments, pubmed-meshheading:10859283-Male, pubmed-meshheading:10859283-Middle Aged, pubmed-meshheading:10859283-Myocardial Infarction, pubmed-meshheading:10859283-Myocardial Reperfusion, pubmed-meshheading:10859283-Recombinant Proteins, pubmed-meshheading:10859283-Thrombolytic Therapy, pubmed-meshheading:10859283-Tissue Plasminogen Activator, pubmed-meshheading:10859283-Treatment Outcome
pubmed:year	2000
pubmed:articleTitle	Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group.
pubmed:publicationType	Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II